MS-NASH Mouse



A more translatable mouse model for testing anti-obesity, antidiabetic, and NAFLD/NASH therapeutic efficacy

The MS-NASH (formerly called FATZO) polygenic obesity mouse model has a functional leptin pathway that more closely mimics human obesity, metabolic syndrome, type 2 diabetes, and NAFLD/NASH


Evaluate your metabolic disease compound efficacy in a translatable mouse model, which more closely mirrors human disease development than conventional murine models.

- MS-NASH mouse features:
 - Polygenic obesity model, with a functional leptin pathway
 - Rapid weight gain, comparable to db/db or ob/ob
 - Males become hyperglycemic at 14 weeks of age
 - Insulin resistance develops at a rapid rate
 - Develops liver steatosis leading to NAFLD/NASH on a Western diet plus fructose
- Developed by crossing C57BL6/J with AKR/J mice and selectively bred to select for obesity, insulin resistance, and hyperglycemia.
- Inbred for 30+ generations.
- Suitable for efficacy studies of anti-obesity and antidiabetic compounds.
- Move your agents into the clinic with greater confidence.


MS-NASH Mouse Model vs Conventional Murine Models


	Human	MS-NASH Mouse	DIO	ob/ob
Polygenic Disease	Yes	Yes	Yes	No
Intact Leptin Pathway	Yes	Yes	Yes	No
Insulin Resistance	Yes	Yes	Diet Induced	Yes
Weight Gain	Yes	Yes	Diet Induced	Yes
Hyperglycemia	Yes	Yes	Minimal	Mild/ Variable

Effect of Rosiglitazone on OGTT in the MS-NASH Mouse



Development of Obesity and Hyperglycemia











DiscoverCrown

Trial translational rodent and NHP models for obesity, diabetes, renal disease, and NAFLD/NASH. crownbio.com/discovercrown